Company Overview and News
Hello and welcome to Globalstar Incorporated Second Quarter 2018 Earnings Conference Call. My name is Michelle, and I will be your operator for today’s conference. At this time all participants are in a listen only mode. Later we will conduct a question and answer session. [Operator Instructions] Please note that today’s conference is being recorded.
Document UNITED STATES
Document UNITED STATES
2018-06-21 zacks - 1
Globalstar, Inc. (GSAT - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GSAT recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
SDOCQ GSAT BBW SDRPQ AMD SDRXP MPC SD SDRXQ
Intelsat S.A.(I - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 16.8% in the past one-month time frame.
June 12, 2018: Here are four stocks trading with heavy volume among 41 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 1.01 to 1 and on the Nasdaq, advancers led decliners by about 1.2 to 1.
HMY GSAT NGD AVP NGDAF NGD HGMCF
2018-06-11 247wallst - 1
June 11, 2018: Here are four stocks trading with heavy volume among 49 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.3 to 1 and on the Nasdaq, advancers led decliners by about 1.23 to 1.
HMY DUKH GSAT ADNT DUK HGMCF
2018-06-08 247wallst - 1
June 8, 2018: Here are four stocks trading with heavy volume among 41 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.43 to 1 and on the Nasdaq, advancers led decliners by about 1.31 to 1.
RPCGF GSAT RPC RPCGY TROVW BERY TROV TROVU RES
2018-05-18 reuters - 3
May 18 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Friday:
GSAT C6L CQP PBBGF T8B PYPL SINGY ENB FUJIF 4901 500470 KR LLOBF VIAB EBBNF CBS VIA ENBBF LLOY CBS.A LNG LYG CBS.WD XRX ENB LLPH LLPK LLPJ TTST LLPE LLPD TATASTEEL TATLY LLPG LLDTF LLD5 LLD7 LLPC LLD6 CPV LLD1 FUJIY SINGF LLD2
2018-05-18 reuters - 2
May 17 (Reuters) - Mudrick Capital Management LP on Thursday filed a lawsuit against satellite communications company Globalstar Inc over its proposed merger with FiberLight LLC, stating that the terms of the deal valued at $1.65 billion are “wildly unfair.”
2017-11-04 - Asif
Mobile Satellite Services Business Globalstar, Inc. (“we,” “us” or the “Company”) provides Mobile Satellite Services (“MSS”) including voice and data communications services globally via satellite. By providing wireless communications services in areas not served or underserved by terrestrial wireless and wireline networks and in circumstances where terrestrial networks are not operational due to natural or man-made disasters, the company seek to meet its customers' increasing desire for connectivity. The company offer voice and data communication services over its network of in-orbit satellites and its active ground stations (“gateways”), which the company refer to collectively as the Globalstar System. The company currently provide the following communications services via satellite. These services are available only with equipment designed to work on its network: two-way voice communication and data transmissions ("Duplex") using mobile or fixed devices; and one-w...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to GSAT / Globalstar, Inc. on message board site Silicon Investor.
as of ET